← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck Sharp & Dohme

Accelerated approvalNew dosing regimenMultiple solid tumors and blood cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An alternative 400 mg every six weeks schedule across adult indications approved at the time, alongside the existing 200 mg every three weeks schedule.

LAMPGEN ANALYSIS

Why it matters

Offered a longer interval between infusions for eligible adults while retaining the prior schedule.

What research teams should watch

Update order sets and preserve timely symptom reporting between infusion visits.

PRIMARY RECORDS

Sources